Akari Therapeutics ADR AKTX

$AKTX It seems there are many hidden gems in Thailandstatin that are waiting to be discovered: PR: "...As we continue to expand our understanding of PH1, we are building an increasingly robust intellectual property foundation for our novel PH1 payload and ADC portfolio.”

$AKTX spread is always ridiculous

$AKTX amended its CEO agreement, boosting the chief's base salary to $625,000, raising bonus potential and granting RSUs and options.

$AKTX Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in Cancers https://akaritx.com/2026/10/01/akari-therapeutics-expands-intellectual-property-portfolio-with-pct-filing-for-adc-payload-related-to-rna-splicing-in-cancers/

$AKTX This is the conclusion of the research from Rice University in 2016, they found Thailanstatin is very promising: (another independent validation of AKTX 's drug)

$AKTX Big pharm are focusing on ADC because ADC will become standard of care for cancers: This recent article explains:

$AKTX This new article explains why drug resistance has become a crisis for big pharma: and why big pharm are buying small ADC companies to address the resistance problems:

$AKTX Here is the latest data that they released on Aug 18, 2026: "Demonstrated encouraging activity following acquired resistance to the first-generation TROP2-directed ADC Trodelvy® (sacituzumab govitecan). Tumors initially treated with Trodelvy subsequently developed resistance and resumed growth. When these resistant tumors were switched from Trodelvy to AKTX-101, tumor growth was again slowed, suggesting that resistance was associated with the Topoisomerase I payload, and that the AKTX-101 PH1 payload mechanism of disrupting RNA splicing can be effective in this resistant setting. These findings support the potential for AKTX-101’s novel PH1 payload to provide therapeutic benefit following prior treatment with first-generation TROP2 ADCs in several areas where these ADCs are currently approved, including potentially breast and lung cancers"